Cirino Botta

35PUBLICATIONS
216CO-AUTHORS
Haematological tumoursAutoimmunityGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jun 12, 2026
Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

|Apr 14, 2026
FcγRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune Dysfunction.

Daniela Cambria, Maria Teresa Cannizzaro, Nunziatina Laura Parrinello

|Apr 14, 2026
Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy.

Cirino Botta, Giorgio Lorenzo Colombo, Sergio Di Matteo

|Feb 04, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.

Annamaria Gullà, Madhav V Dhodapkar, Hermann Einsele

|Jan 10, 2026
Immune-Based Biomarkers as Predictors of Mortality in ECMO Therapy for Severe COVID-19 ARDS: Insights from a Retrospective Study.

Rosalia Busà, Giovanna Panarello, Alessia Gallo

Pageof 6

Frequent Collaborators

6 joint publications

Bruno Paiva

5 joint publications

Juan-Jose Garcés

5 joint publications

Anna Maria Corsale

5 joint publications

Massimo Gentile